6 hours Ago By Defense World Staff
ALX Oncology ( NASDAQ:ALXO – Get Free Report ) was downgraded by Jefferies Financial Group from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, Marketbeat Ratings reports. They presently have a $2.00 price target on the stock, down from their previous price target of $12.
00. Jefferies Financial Group’s price target suggests a potential upside of 23.46% from the company’s previous close.
Other analysts have also recently issued reports about the company. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a report on Wednesday. HC Wainwright reissued a “buy” rating and set a $25.
00 price target on shares of ALX Oncology in a research report on Wednesday. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.
com, ALX Oncology has a consensus rating of “Moderate Buy” and an average target price of $8.50. Get Our Latest Stock Analysis on ALX Oncology ALX Oncology Trading Up 9.
5 % Insiders Place Their Bets In related news, Director Rekha Hemrajani purchased 30,000 shares of ALX Oncology stock in a transaction dated Monday, December 2nd. The shares were acquired at an average cost of $1.55 per share, with a total value of $46,500.
00. Following the purchase, the director now owns 33,000 shares of the company’s stock, valued at approximately $51,150. The trade was a 1,000.
00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website . 33.
40% of the stock is owned by insiders. Hedge Funds Weigh In On ALX Oncology A number of hedge funds have recently made changes to their positions in the stock. Point72 Asset Management L.
P. acquired a new position in ALX Oncology during the second quarter worth $1,834,000. GSA Capital Partners LLP purchased a new stake in shares of ALX Oncology in the 3rd quarter valued at $88,000.
Marshall Wace LLP lifted its stake in ALX Oncology by 423.0% during the 2nd quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock worth $3,833,000 after acquiring an additional 514,133 shares in the last quarter.
SG Americas Securities LLC boosted its holdings in ALX Oncology by 33.6% during the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after acquiring an additional 6,888 shares during the period.
Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in ALX Oncology by 394.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after acquiring an additional 5,200 shares in the last quarter.
Hedge funds and other institutional investors own 97.97% of the company’s stock. About ALX Oncology ( Get Free Report ) ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.
The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. Featured Stories Five stocks we like better than ALX Oncology How to Calculate Stock Profit Opal Fuels CEO on Steering the Future of Renewable Natural Gas How to Know if a Stock Pays Dividends and When They Are Paid Out MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win What is the S&P/TSX Index? 2 Underrated Quantum Computing Companies Starting to Rally Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter .
.
